Trials / Completed
CompletedNCT00356642
Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis
A Randomised, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Ten Day Repeat Topical Applications of GW842470X Cream on the Skin of Patients With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 67 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study of this study is to investigate the safety, tolerability and pharmacokinetics of GW842470X in patients with atopic dermatitis. GW842470X is an inhibitor of phosphodiesterase 4 (PDE4).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW842470X | GW842470X will be available as a yellow smooth water-in-oil cream. |
| DRUG | Placebo | GW842470X matching placebo will be available as a yellow smooth water-in-oil cream. |
Timeline
- Start date
- 2005-06-10
- Primary completion
- 2005-12-21
- Completion
- 2005-12-21
- First posted
- 2006-07-26
- Last updated
- 2017-09-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00356642. Inclusion in this directory is not an endorsement.